Phase 3 N=613 Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
Small-cell Lung Cancer
Primary: Overall Survival (OS) — 8.6; 7.6 months — p=0.9029
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=35 VISmodegib for ORbital and Periocular Basal Cell Carcinoma
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
Phase 3 N=46 Effects of Pneumatic Vitreolysis on Vitreomacular Traction
Vitreomacular Traction
Primary: Proportion of Eyes With Central Vitreomacular Traction Release Without Rescue Vitrectomy — 78; 9 percentage of eyes
N/A N=12 Assessing Adherence to Home Telemedicine in Individuals With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Participants With Home Device Measurement Collection Adherence — 63 percentage of participants
N/A N=160 Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence
Atrial Fibrillation · Medication Adherence
Primary: Medication Adherence — 93.08; 89.52 percentage of doses recorded as taken — p=0.28
N/A N=47 At-home Transcranial Alternating Current Stimulation During Multitasking
Multitasking Behavior
Primary: Multitasking Performance Cost (Neuroracer Performance Change From Baseline) — 45.3; 37.9 percentage change of d' — p=0.55
Phase 3 N=6 Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma
Osteosarcoma
Primary: The Number of Outpatient High Dose Methotrexate Courses Which Result in an Inpatient Hospital Admission. — 0 courses of MTX
N/A N=172 Addressing COVID-19 Mental Health Problems Among US Veterans
Brief Video-based Intervention · Vignette Based Intervention · Non Intervention Control Arm
Primary: Help Seeking Intention — 7.4; 7.9; 7.3; 8.2 units on a scale — p=0.031
N/A N=914 ERANet-LAC CODE: International Care Of the Dying Evaluation
Neoplasms · Bereavement · Quality of Life
Primary: CODE (Care Of the Dying Evaluation) Questionnaire Item 30 Score for Relatives' Perception of How Much of the Time the Deceased Patient Was Treated With Dignity and…
Phase 2 N=121 A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
Nonalcoholic Fatty Liver
Primary: Relative Change in the Percentage of Liver Fat Mass (Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction [MRI-PDFF]) From Baseline to Week 12/End of…
Phase 2 N=41 BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
Marginal Zone Lymphoma · Follicular Lymphoma · Diffuse Large B-Cell Lymphoma
Primary: Overall Response Rate (ORR) As Measured By The Investigator — 35; 56.3; 60.0 Percentage of Participants
Phase 2 N=8 MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Inherited Metabolic Disorders (IMD)
Primary: Number of Participants With Engraftment — 6; 2 Participants
Phase 2 N=91 A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Primary: Determination of Maximum Tolerated Dose and / or Recommended Dose and Dosing Regimen of MOR03087 — 16; 16; 16; 16 mg/kg
N/A N=763 Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Total Score at Month 12 — 7.75; 7.74; 7.72; 7.78 Units on a scale — p=0.001
N/A N=30 An Evaluation of Proglucamune in the Treatment of Protective Qi Insufficiency
Protective Qi Insufficiency
Primary: Change of Protective Qi Score (PQS) Determined by a Standardized Assessment — 6.3; 6.8; 7.17; 7.27 units on a scale — p=<0.0001